Prostate Cancer, Hereditary, 14

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

RNASEL, HOXB13, ELAC2, MSR1, CHEK2, BRCA2, BRCA1, CDKN1B, MSMB, SRD5A2, CDH1, EPHB2, NBN, TTC28, LARP4B, KDM2A, BCL2L11, TSHZ1, HAUS6, DENND4B, ADGRG1, MBD2, BCAS1, PPFIBP2, TCF7L2, HNF1B, TCF4, B3GAT1, MAD1L1, UHRF1BP1, COL23A1, RN7SKP114, RNU6-491P, RNU6-148P, THEG5, MEIS1-AS3, OACYLP, DUBR, RASSF3, CDCA7, RNF43, MOB2, ATAT1, SUGCT, RFX7, PKNOX2, FBRSL1, KNL1, RNLS, EMSY, RNU6-456P, DOCK2, PAX9, MYO9B, MMP14, POU2F2, MBNL1, MAP2K1, ITGB8, INCENP, CHD3, HLA-DOA, DNMT3B, MECOM, CASP8, BCL2, ATM, ARHGAP6, TOR1A, KLK3, PCAP, CBX4, HPCX, AMACR, KLF6, AR, HPC3, CYP17A1, MYC, NPEPPS, PROS1, PSAT1, PLAG1, GSTK1, CYP19A1, RGS8, BRIP1, SLCO6A1, MIR888, ARL11, CYP1B1, CYP1A1, RGSL1, SULT1A1, PALB2, ERG, RASA1, PTEN, TP53, VDR, SPOP, PPM1D, PPP2R2A, PON1, PKHD1, LZTS1, MLH1, LGALS8, KLK2, RASA2, PINX1, GSTT1, PDSS2, GSTP1, GSTM1, CT55

Drugs

Mitoxantrone ( NOVANTRONE )

Interested in hearing about new therapies?

For a general discussion of hereditary prostate cancer, see 176807.

Mapping

In a large genomewide association study (GWAS) of prostate cancer, Thomas et al. (2008) detected a single-nucleotide polymorphism (SNP) on chromosome 11q13, rs10896449, the G allele of which was significantly associated with prostate cancer risk (p = 1.76 x 10(-9)). The rs10896449 SNP is located 67 kb upstream of a gene overexpressed in myeloma, MYEOV (605625).

Eeles et al. (2008) conducted a genomewide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at or before the age of 60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (less than 0.5 ng/ml). They analyzed these samples for 541,129 SNPs using the Illumina Infinium platform. Initial putative associations were confirmed using a further 3,268 cases and 3,366 controls. Eeles et al. (2008) identified a SNP on chromosome 11, rs7931342, that was significantly associated with prostate cancer risk (p = 1.7 x 10(-12)). They described the region on chromosome 11 in which the SNP rs7931342 is located as 'a gene desert.'

In a prostate cancer genomewide association follow-up study, Gudmundsson et al. (2009) refined a previous association signal on 11q13 with rs11228565A (odds ratio = 1.23, p = 6.7 x 10(-12)). In a multivariate analysis using 22 prostate cancer risk variants typed in the Icelandic population, Gudmundsson et al. (2009) estimated that carriers in the top 1.3% of the risk distribution are at 2.5 times greater risk of developing the disease than members of the general population.